Navigation Links
Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
Date:7/29/2010

istory of use of these products."

Study Design

COR-I was a 56-week placebo-controlled, double-blind randomized trial enrolling patients whose body-mass index (BMI) was between 30-45 kg/m(2) for patients with uncomplicated obesity, or BMI 27-45 kg/m(2) with controlled hypertension or dyslipidemia, or both. 1742 patients were randomized to receive either Contrave32, Contrave16 (16mg naltrexone SR/360mg bupropion SR), or placebo in a 1:1:1 ratio. Thirty-four sites in the United States participated in the study.

About Contrave

Contrave is an investigational combination therapy believed to address both physiological and behavioral drivers of obesity. The two components of this combination therapy act in a complementary manner in the central nervous system. The central pathways targeted by this treatment are involved in controlling the balance of food intake and metabolism, and regulating reward-based eating behavior. In clinical trials, Contrave was shown to help obese patients initiate and sustain significant weight loss, improve important markers of cardiometabolic risk and increase ability to control eating. The U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 and the Prescription Drug User Fee Act (PDUFA) action date has been set for January 31, 2011.

About the Contrave Clinical Development Program

All four trials in the COR Phase 3 program (COR-I, COR-II, COR-BMOD and COR-Diabetes) were randomized, double-blind, placebo-controlled trials. The co-primary endpoints were the proportion of patients achieving at least 5% weight loss and percent change in bo
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  Daktari Diagnostics was honored at ... Technology in the Service of Society Award. IEEE President and ... Barry L. Shoop presented the award to Principal Scientist ... ceremony was held Saturday, June 20, 2015, at the historic ... . "I have spent more than 3 ...
(Date:6/29/2015)... June 29, 2015  New guidelines released today ... Association give hope for better outcomes to the ... acute ischemic stroke each year. Stryker,s Trevo ® ... used in the clinical trials that provided data ... guidelines strongly recommend endovascular therapy with stent retrievers ...
(Date:6/29/2015)... Nev. , June 29, 2015  PDL BioPharma, ... has entered into a credit agreement with CareView Communications, ... up to $40 million of secured debt financing. CareView ... focused on patient care monitoring. Under the ... $40 million of debt financing in two tranches of ...
Breaking Medicine Technology:Daktari Honored with IEEE Spectrum Award 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4
... Oct. 24, 2011 Alexza Pharmaceuticals, Inc. (Nasdaq: ... & Drug Administration (FDA) has scheduled a meeting of ... 2011, at which the ADASUVE New Drug Application (NDA) ... that the FDA had accepted the resubmission of the ...
... 2011 Covance Inc. (NYSE: CVD ) ... Shanghai, China, has received Good Laboratory Practice (GLP) certification ... the Organization for Economic Cooperation and Development (OECD). The ... toxicology, in-vivo PK screening, and metabolism services. ...
Cached Medicine Technology:Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011 2Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011 3Covance Receives Good Laboratory Practice Certification for Its Early Development Facility in Shanghai, China 2
(Date:6/29/2015)... NEW YORK (PRWEB) , ... June 29, 2015 ... ... apnea (OSA) is now being offered at NewYork-Presbyterian/Weill Cornell Medical Center. The device ... Administration and is an alternative to continuous positive airway pressure (CPAP), the current ...
(Date:6/29/2015)... ... June 29, 2015 , ... Human Factors ... Webinar**, July 16, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/humanfactors ... human factors engineering to the design of new products as well as to ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... developed a new approach to build nearly complete genomes by combining high-throughput DNA ... genomic variation, critically important for their association with human disease, but previously difficult ...
(Date:6/29/2015)... OH (PRWEB) , ... June 29, 2015 , ... ... support to healthcare providers for patients with certain neuropsychiatric and chronic pain conditions, ... President and CEO. , The appointments include: Peter Donato, Senior Vice President, Chief ...
(Date:6/29/2015)... ... June 29, 2015 , ... OR Manager announced Monday the launch of an ... well as a redesigned logo and weekly eLetter. The website contains the same informational ... and easier to navigate. , In addition to a refreshed look, http://www.ormanager.com ...
Breaking Medicine News(10 mins):Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 3Health News:OR Manager Launches New Website 2
... By Jenifer Goodwin HealthDay Reporter , ... a good predictor of academic performance, but not necessarily ... tested the IQs and reading, spelling and math abilities ... the children,s social functioning through parental and teacher reports ...
... HealthDay Reporter , TUESDAY, Nov. 23 (HealthDay News) ... the year, many Americans will soon be subjected to radiation-emitting ... tide of concerns and complaints in recent weeks over body ... is too low to pose any serious health threat. ...
... 2010) - Even though most people are aware that good ... mother and child, misunderstandings about the safety of dental care ... dentist. The fact is that dentists can create a treatment ... adverse effects of oral disease during pregnancy. During the ...
... Reporter , TUESDAY, Nov. 23 (HealthDay News) -- Being born just ... child,s IQ and ability to pay attention, new research suggests. ... to those born between 34 to 36 weeks (called "late ... twice the risk of having an IQ score below 85 and ...
... HealthDay Reporter , MONDAY, Nov. 22 (HealthDay ... antioxidant cousin, alpha-carotene, in fruits and vegetables can lower ... disease and cancer, new research suggests. Both ... because of the red, yellow and orange coloring they ...
... , TUESDAY, Nov. 23 (HealthDay News) ... and efficiency while preventing sudden death among heart ... survival in real-world situations as they are in ... finding is based on an analysis of nearly ...
Cached Medicine News:Health News:For Autistic Kids, IQ May Not Predict School Achievement 2Health News:For Autistic Kids, IQ May Not Predict School Achievement 3Health News:Airport Body Scanners Safe, Experts Say 2Health News:Airport Body Scanners Safe, Experts Say 3Health News:Expecting? Don't neglect your teeth 2Health News: Children Born 'Late Pre-Term' More Prone to Low IQ 2Health News: Children Born 'Late Pre-Term' More Prone to Low IQ 3Health News:Eat Your Fruits & Veggies for Longer Life 2Health News:Eat Your Fruits & Veggies for Longer Life 3Health News: Implanted Heart Devices Have 'Real-World' Benefits: Study 2Health News: Implanted Heart Devices Have 'Real-World' Benefits: Study 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: